Pulmonary Peptide Drug Delivery: DPIs, Nebulizers, and MDIs for Peptide Therapeutics

The lungs are one of the most promising routes for delivering peptide drugs. The lung surface is huge, the tissue is thin, and blood flow is rich.

This combination makes inhaled peptide drugs both practical and powerful. Understanding which delivery device works best is the key to a successful pulmonary peptide program.

Why the Lungs Are a Good Route for Peptide Drugs

The human lung has a surface area of about 70 square meters. That is roughly the size of a tennis court. Most of this surface is available for drug absorption.

The alveoli are the tiny air sacs at the end of the airway. Their walls are only one cell thick, and they are surrounded by a dense network of blood vessels. Drugs that reach the alveoli absorb quickly into the bloodstream.

For peptide drugs, this matters because:

• Fast absorption: Peptides can reach the blood within minutes
• Avoidance of first-pass metabolism: Inhaled drugs bypass the liver on the first pass
• Lower enzyme activity: The lung has fewer proteases than the gut
• Large surface area: High absorption potential with the right particle size

"The lung is an underutilized portal for systemic drug delivery. For peptides, it offers a clear advantage in bioavailability over oral routes, and it is far more patient-friendly than injections for chronic conditions." - Dr. Anthony Hickey, RTI International

Exubera, the first inhaled insulin product, was approved by the FDA in 2006. It proved that the lungs could deliver a therapeutic peptide systemically. Though Exubera was withdrawn for commercial reasons, it validated the science. A newer inhaled insulin, Afrezza, was approved in 2014 and is still used today.

David Edwards, Professor of the Practice of Bioengineering at Harvard University, wrote in Inhaling to Live (2010): "Inhaled insulin demonstrated that the lung can deliver therapeutic peptides systemically, but the real breakthrough will come when we optimize particle engineering for molecules beyond insulin."

Challenges of Pulmonary Peptide Delivery

The lung is also a defensive organ. It is designed to keep foreign particles out. This creates several challenges for inhaled peptide drugs.

Mucociliary clearance: The airways are lined with mucus and hair-like cilia. Particles that land in the upper airways get swept out quickly. Only particles that reach the deep lung avoid this fate.

Macrophage clearance: Alveolar macrophages patrol the deep lung. They engulf and destroy particles, including drug carriers. This can reduce the effective dose that reaches the bloodstream.

Humidity: The lungs are warm and wet. This can cause powder particles to clump, reducing the fine particle fraction that reaches the alveoli.

Peptide stability: Heat, shear forces, and pH changes during aerosolization can damage peptides. Formulation must protect the peptide through the delivery process.

Exubera, the first FDA approved inhaled insulin, proved pulmonary peptide delivery works but flopped commercially because the device was the size of a tennis ball canister, scaring off patients and physicians alike.

Dry Powder Inhalers (DPIs): The Most Stable Option

Dry powder inhalers deliver a dry powder formulation directly to the lungs. The patient inhales through the device, and their breath creates the airflow needed to disperse and carry the powder into the airways.

DPIs have major advantages for peptide drugs:

• No propellant needed: Simpler formulation and more environmentally friendly
• Better stability: Dry powders are more stable than liquid solutions
• Portable: Small, easy to carry and use
• No coordination required: The patient's breath activates the dose

Aerosol Particle Size

The most critical parameter in DPI development is aerodynamic particle size. Particles must be in the right size range to reach the deep lung:

Particle Size	Deposition Site	Outcome
> 10 micrometers	Mouth and throat	Swallowed, not absorbed
5-10 micrometers	Upper airways	Mucociliary clearance
1-5 micrometers	Deep lung (alveoli)	Systemic absorption
< 0.5 micrometers	Exhaled	Lost from the dose

The ideal particle size for deep lung delivery is 1 to 5 micrometers. This is called the fine particle fraction (FPF), and it is the key quality metric for inhaled products.

DPI Formulation Strategies for Peptides

Getting a peptide into a 1-5 micron powder that flows well and disperses in airflow is complex. Common strategies include:

Spray drying: The peptide is dissolved in a liquid and sprayed through a nozzle into hot air. The liquid evaporates instantly, leaving tiny dry particles. Spray drying is the most common method for making inhalable peptide powders.

Spray freeze-drying: The solution is sprayed into liquid nitrogen, freezing the droplets instantly. The frozen particles are then freeze-dried. This is gentler on sensitive peptides.

Jet milling: Larger particles are ground down to micron size using high-velocity air jets. This works for stable peptides but can damage more fragile ones.

Carrier blending: Small drug particles are blended with large lactose carrier particles. The drug sticks to the carrier for handling, then detaches during inhalation. This is standard in asthma DPI products.

Nebulizers: Liquid Delivery to the Lungs

Nebulizers convert a liquid drug solution or suspension into a fine mist of droplets. The patient breathes the mist through a mouthpiece over several minutes.

Nebulizers are the oldest form of inhaled drug delivery. They are widely used in hospitals and for patients who cannot use handheld devices.

Types of Nebulizers

Nebulizer Type	How It Works	Advantage
Jet nebulizer	Compressed air breaks liquid into droplets	Low cost, widely available
Ultrasonic nebulizer	Ultrasound vibrations create droplets	Quiet, faster delivery
Vibrating mesh nebulizer	Mesh with tiny holes vibrates to produce droplets	Most efficient, least drug waste

Vibrating mesh nebulizers (like the PARI eFlow or Aerogen Solo) are best for expensive peptide drugs. They waste the least drug because the mesh produces a very fine, consistent aerosol with minimal residual volume.

The challenge with nebulizers and peptides is stability. The nebulization process exposes the drug to shear forces, air-liquid interfaces, and sometimes heat (in ultrasonic models). These can denature or aggregate peptides.

Formulation strategies for nebulized peptides include:

• Adding stabilizers like sucrose or trehalose
• Using low-temperature nebulizers (vibrating mesh)
• Optimizing pH and ionic strength
• Adding surfactants like polysorbate 80 at low concentrations

Inhaled tobramycin (TOBI) is one of the most commercially successful nebulizer products, generating over $400 million annually. Although not a peptide, it demonstrated that the inhaled route can support major commercial products for chronic conditions.

Metered Dose Inhalers (MDIs): Pressurized Precision

Metered dose inhalers use a pressurized canister to release a precise dose of drug with each actuation. The patient presses the canister and inhales at the same time.

MDIs were the standard for asthma drugs for decades. For peptide delivery, they have some specific challenges:

• Propellants (HFA) must be compatible with the peptide
• Peptides tend to stick to metal canisters and rubber seals
• Liquid suspension or solution formulations are needed
• Coordination between actuation and inhalation is required

Some patients cannot coordinate the press-and-breathe action. A spacer device attached to the MDI can help by holding the aerosol cloud until the patient inhales.

For most peptide drugs, DPIs or nebulizers are preferred over MDIs because of better stability and simpler formulation requirements. For additional context, the NIH National Library of Medicine research database offers relevant guidance on this topic.

When selecting a CDMO for your inhaled peptide program, prioritize partners with spray drying capabilities and cascade impactor testing in house, because outsourcing aerodynamic particle size distribution testing to a third party adds weeks to every formulation iteration.

Comparing Delivery Devices for Inhaled Peptides

Feature	DPI	Nebulizer	MDI
Peptide stability	Best (dry)	Moderate	Challenging
Patient ease of use	Moderate	Easy (passive)	Requires coordination
Portable	Yes	No (mostly)	Yes
Dose precision	Good	Variable	Good
Cost	Moderate	Low to high	Low
Deep lung deposition	Good	Good	Variable
Best for	Chronic, home use	Acute, hospital	Established drugs

Key Regulatory Considerations

Inhaled drug products face a detailed regulatory review. The FDA requires extensive characterization of the aerosol performance.

Required testing includes:

• Cascade impaction: Measures the size distribution of aerosol particles
• Fine particle fraction: Percentage of dose in the 1-5 micron range
• Emitted dose uniformity: Consistency across the life of the device
• Delivered dose: Total drug actually released per actuation
• Device robustness: Performance across temperature and humidity conditions

For peptide products, additional testing of peptide integrity (no aggregation, no denaturation) throughout the delivery process is expected.

Clinical Programs in Inhaled Peptide Delivery

Beyond insulin, several peptide drugs are being developed for inhalation:

• Inhaled GLP-1 agonists: For diabetes with potentially better tolerability
• Inhaled PTH/PTHrP analogs: For osteoporosis treatment
• Inhaled antimicrobial peptides: For treating lung infections
• Inhaled interferon peptides: For pulmonary fibrosis and lung cancer
• Inhaled oxytocin: Being studied for autism spectrum disorder

---

Matching your peptide's stability profile to the right inhaler platform (DPI, nebulizer, or MDI) early in development prevents costly reformulation work downstream.

FAQs About Pulmonary Peptide Drug Delivery

Can peptides really be absorbed through the lungs?

Yes. The lung's thin alveolar membrane and rich blood supply make it an effective absorption site. Exubera and Afrezza (inhaled insulin) are real-world proof that peptide drugs can be absorbed systemically through the lungs at therapeutic levels.

What is the fine particle fraction and why does it matter?

The fine particle fraction (FPF) is the percentage of the inhaled dose made up of particles in the 1-5 micron range. Only these particles reach the deep lung where absorption occurs. A higher FPF means more drug reaches the right place and less is wasted in the upper airways.

Is spray drying safe for peptides?

Spray drying can stress peptides with heat, shear forces, and surface tension at the air-liquid interface. However, with the right formulation (stabilizers like sugars and amino acids) and optimized spray-drying conditions (low temperature, appropriate atomization), most peptides can be spray dried with minimal damage.

How does a nebulizer differ from a DPI?

A nebulizer delivers a liquid aerosol and requires the patient to breathe normally for several minutes. A DPI delivers a dry powder and requires a strong, fast inhalation. DPIs are faster and more portable. Nebulizers are easier for patients who cannot generate the needed inhalation force.

What particle size is needed for systemic versus local lung delivery?

For systemic delivery (drug absorbed into the blood), particles should be 1-3 micrometers to reach the alveoli. For local lung effects (like treating asthma or lung infection), slightly larger particles (3-5 micrometers) that deposit in the larger airways may also be effective.

---

Find Inhaled Peptide Delivery Scientists With PeptideStaff

Building a pulmonary peptide delivery program requires scientists who understand aerosol physics, peptide stability, device engineering, and inhalation pharmacokinetics. This is a rare combination.

PeptideStaff connects pharma and biotech organizations with seasoned inhalation scientists, formulation experts, and regulatory specialists who specialize in inhaled biologics and peptides.

Contact PeptideStaff to find inhaled peptide delivery experts for your program.